Harvard Bioscience

Harvard Bioscience Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Harvard Bioscience (HBIO) as of Nov 6, 2026 is 153.95. In the previous year, Cash Conversion Cycle (CCC) was 228.77 — a change of -32.70% (lower).

Cash Conversion Cycle

153.95

YoY

-32.70%

Last updated:

Cash Conversion Cycle (CCC) of Harvard Bioscience is 2025 153.95 . Cash Conversion Cycle (CCC) of Harvard Bioscience was 2024 228.77 . It decreases by -32.70% lower compared to the previous year.

The Harvard Bioscience Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
177.33 USD
Jan 1, 2019
182.74 USD
Jan 1, 2020
198.59 USD
Jan 1, 2021
228.41 USD
Jan 1, 2022
192.73 USD
Jan 1, 2023
203.81 USD
Jan 1, 2024
228.77 USD
Jan 1, 2025
153.95 USD
The Harvard Bioscience Cash Conversion Cycle history
YEARCash Conversion CycleYoY
153.95-32.70%
228.77+12.25%
203.81+5.75%
192.73-15.62%
228.41+15.02%
198.59+8.67%
182.74+3.05%
177.33+9.51%
161.93+12.19%
144.34+2.11%
141.36-0.23%
141.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harvard Bioscience Stock analysis

What does Harvard Bioscience do? Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world. Harvard Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harvard Bioscience stock

Cash Conversion Cycle (CCC) of Harvard Bioscience is 153.95 in 2025.

Cash Conversion Cycle (CCC) of Harvard Bioscience changed from 228.77 to 153.95, representing a -32.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Harvard Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Harvard Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Harvard Bioscience

All Key Metrics — Harvard Bioscience